Compare Stocks → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BFRANASDAQ:EVFMNASDAQ:NBSENASDAQ:OPTN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRABiofrontera$2.60$2.95$2.09▼$7.54$73.73M1.0227,512 shs7,263 shsEVFMEvofem Biosciences$0.01$0.02$0.01▼$3.75$766K-1.12782,114 shs178,028 shsNBSENeuBase Therapeutics$0.44+4.7%$0.68$0.39▼$4.80$1.66M0.83202,576 shs25,441 shsOPTNOptiNose$0.91-2.2%$1.47$0.86▼$2.10$101.95M-0.24832,803 shs23.36 million shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRABiofrontera0.00%0.00%0.00%0.00%0.00%EVFMEvofem Biosciences+16.04%+9.56%-22.56%-50.00%-99.43%NBSENeuBase Therapeutics0.00%+0.26%-57.44%-32.12%-83.97%OPTNOptiNose-4.38%-9.28%-38.31%-36.62%-47.72%The World's First "$20 Trillion Drug?" (Ad)One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRABiofronteraN/AN/AN/AN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOPTNOptiNose3.6315 of 5 stars3.52.00.04.20.02.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRABiofronteraN/AN/AN/AN/AEVFMEvofem Biosciences2.00HoldN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AOPTNOptiNose3.00Buy$4.00341.99% UpsideCurrent Analyst RatingsLatest EVFM, OPTN, BFRA, and NBSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/18/2024OPTNOptiNoseLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$3.00 ➝ $4.003/11/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRABiofrontera$36.19M2.04N/AN/A$0.35 per share7.43EVFMEvofem Biosciences$18.22M0.04$1.42 per share0.01($2.64) per share-0.01NBSENeuBase TherapeuticsN/AN/AN/AN/A$11.04 per shareN/AOPTNOptiNose$70.99M1.44N/AN/A($0.77) per share-1.18Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRABiofrontera-$14.88M-$0.73N/A∞N/A-59.44%-93.31%-24.02%N/AEVFMEvofem Biosciences$52.98M-$7.62N/A∞N/A290.81%-90.20%331.20%4/26/2024 (Estimated)NBSENeuBase Therapeutics-$4.37M-$7.70N/A∞N/AN/A-99.74%-60.13%5/9/2024 (Estimated)OPTNOptiNose-$35.48M-$0.32N/AN/AN/A-50.06%N/A-33.05%5/9/2024 (Estimated)Latest EVFM, OPTN, BFRA, and NBSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023EVFMEvofem BiosciencesN/A-$0.44-$0.44-$0.44N/A$4.84 million3/7/202412/31/2023OPTNOptiNose-$0.10-$0.09+$0.01-$0.09$19.90 million$19.87 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRABiofronteraN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRABiofrontera0.131.261.13EVFMEvofem BiosciencesN/A0.130.10NBSENeuBase TherapeuticsN/A2.872.87OPTNOptiNoseN/A0.600.55OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRABiofrontera60.07%EVFMEvofem Biosciences0.22%NBSENeuBase Therapeutics12.37%OPTNOptiNose85.60%Insider OwnershipCompanyInsider OwnershipBFRABiofronteraN/AEVFMEvofem Biosciences0.21%NBSENeuBase Therapeutics13.90%OPTNOptiNose2.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBFRABiofrontera13828.36 millionN/ANot OptionableEVFMEvofem Biosciences3753.96 million53.85 millionNot OptionableNBSENeuBase Therapeutics373.75 million3.23 millionNot OptionableOPTNOptiNose132112.65 million110.17 millionNot OptionableEVFM, OPTN, BFRA, and NBSE HeadlinesSourceHeadlineWhy Is OptiNose (OPTN) Stock Up 12% Today?investorplace.com - April 25 at 10:51 AMOptinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 millionglobenewswire.com - April 25 at 7:00 AMOptinose to Present at Needham Virtual Healthcare Conferencemsn.com - April 7 at 9:30 AMOptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years agofinance.yahoo.com - April 6 at 2:26 PMOptinose to Present at the Needham Virtual Healthcare Conferenceglobenewswire.com - April 4 at 4:01 PMMichael F. Marino III Sells 15,059 Shares of OptiNose, Inc. (NASDAQ:OPTN) Stockinsidertrades.com - March 20 at 7:32 AMOptinose, Inc.: XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polypsfinanznachrichten.de - March 16 at 1:18 PMOptiNose granted FDA nod to expand labeling for sinusitis therapymsn.com - March 16 at 1:18 PMBucks County's Optinose wins FDA approval for wider use of flagship productbizjournals.com - March 15 at 8:58 PMXHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polypsglobenewswire.com - March 15 at 3:34 PMOptinose primed for FDA ruling on Xhance that could 'reshape' its futurebizjournals.com - March 13 at 8:17 PMUS$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Resultsfinance.yahoo.com - March 10 at 1:35 PMOptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 10 at 12:26 AMOptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 8 at 12:56 PMOptiNose Full Year 2023 Earnings: EPS Beats Expectationsfinance.yahoo.com - March 8 at 7:55 AMOptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ...finance.yahoo.com - March 7 at 4:14 PMOPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023investorplace.com - March 7 at 2:01 PMOptinose, Inc.: Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlightsfinanznachrichten.de - March 7 at 10:19 AMOptinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlightsfinance.yahoo.com - March 7 at 10:19 AMOptiNose reports mixed results; initiates Q1 and FY24 outlookmsn.com - March 7 at 10:19 AMOptiNose: Q4 Earnings Snapshotwashingtonpost.com - March 7 at 10:19 AMOptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimateszacks.com - March 7 at 9:16 AMOptinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlightsglobenewswire.com - March 7 at 7:00 AMOptiNose's Earnings: A Previewbenzinga.com - March 6 at 6:45 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiofronteraNASDAQ:BFRABiofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.Evofem BiosciencesNASDAQ:EVFMEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.NeuBase TherapeuticsNASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.OptiNoseNASDAQ:OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.